Roche Partners With China's Hansoh in Deal That Could Top $15 Billion
By Adria Calatayud
Roche Holding entered into a collaboration and licensing agreement with China's Hansoh Pharmaceutical Group, in a deal that could exceed $15 billion.
As part of the agreement, Hansoh will receive $400 million upfront, $110 million after a year and be eligible for potential payments subject to targets totaling more than $15 billion, it said Monday. Hansoh would also get royalties on potential sales if the products are commercialized, it added.
The collaboration aims to advance a portfolio of antibody-drug conjugates across multiple cancer types, including two programs from Hansoh as well as multiple others powered by its technology platform and based on drug targets proposed by Roche, Hansoh said.
Hansoh said it would be in charge of leading the early development of the programs, with Roche assuming responsibility outside China, Hong Kong, Macau and Taiwan after the completion of early-stage clinical trials.
The deal expands the relationship between the two companies and continues a dealmaking streak by the Swiss drugmaker in China.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
October 19, 2026 08:11 ET (12:11 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
United States